DL-Histidine HCl Synthesis Route and Manufacturing Process
- Chemical Identity: DL-Histidine Monohydrochloride Monohydrate (CAS: 123333-71-1) is a critical amino acid derivative used in pharmaceutical formulations.
- Process Efficiency: Optimized manufacturing processes utilize controlled solvent ratios and HCl gas treatment to maximize yield and minimize impurities.
- Quality Standards: Final products must meet rigorous pharmaceutical grade specifications, including HPLC purity profiles and residual solvent limits.
The production of DL-Histidine HCl represents a sophisticated segment of fine chemical manufacturing, requiring precise control over reaction kinetics and downstream purification. As a vital amino acid derivative, this compound serves as an intermediate in various pharmaceutical applications and nutritional supplements. The chemical structure, formally known as 2-Amino-3-(1H-imidazol-4-yl)propanoic acid hydrochloride, demands a robust synthesis route that ensures consistency across large-scale batches. Manufacturers must balance reaction yields with the stringent requirements of global regulatory bodies.
Overview of DL-Histidine HCl Synthesis Route
The foundational manufacturing process for DL-Histidine hydrochloride typically involves the conversion of the free base into its hydrochloride salt form. While fermentation is a common starting point for the amino acid backbone, the chemical transformation into the stable salt requires careful handling of acidic conditions. The process begins with the dissolution of the histidine base in a suitable solvent system. Technical data suggests that maintaining specific water-to-organic solvent ratios is critical for optimizing reaction speed and product quality. For instance, controlling water content within a range of 0.9 to 1.5 parts per 100 parts of organic solvent can significantly influence the hydrolysis of intermediates and the final crystallization profile.
Temperature control is another pivotal factor. Reaction vessels are often heated to reflux conditions, typically between 145°C and 165°C, depending on the solvent boiling point. This thermal energy drives the reaction to completion while minimizing the formation of unwanted by-products. Following the reaction phase, the solution is cooled to facilitate precipitation. The introduction of hydrogen chloride gas must be managed precisely to avoid violent exothermic events and ensure uniform salt formation. This step is crucial for achieving the desired stoichiometry and preventing the co-precipitation of impurities.
Industrial Scale Manufacturing Process Optimization
Scaling the synthesis route from laboratory to industrial production introduces challenges related to heat transfer and mixing efficiency. To maintain pharmaceutical grade standards, manufacturers employ specialized reactor setups equipped with mechanical stirrers, condensers, and nitrogen purge systems. The use of inert gas atmospheres prevents oxidation and maintains the stability of the imidazole ring during processing. Solvent selection is equally important; common systems include cyclohexanol, toluene, and ethanol. These solvents are chosen for their ability to dissolve reactants while allowing the final product to crystallize efficiently upon cooling.
Crystallization kinetics are optimized by controlling the cooling rate. Rapid cooling can lead to small crystal sizes and solvent inclusion, whereas controlled cooling to 0-5°C promotes the formation of large, pure crystals. The crude product is often subjected to trituration with solvents like methylene chloride or ethanol to remove residual organic impurities. This washing step is essential for reducing the levels of residual solvents to meet safety guidelines. Furthermore, vacuum drying at temperatures between 55°C and 65°C ensures the removal of moisture without degrading the monohydrate structure.
When sourcing high-purity industrial purity, buyers should evaluate the manufacturer's capability to control these critical process parameters. Variations in acid equivalency during salt formation can dramatically alter the impurity profile. Data indicates that using approximately 0.5 to 0.6 molar equivalents of hydrochloric acid relative to the free base often provides the most favorable balance between yield and purity, limiting the presence of basic impurities that might co-precipitate.
Quality Control in Amino Acid Synthesis
Quality assurance protocols are integral to the production of DL-Histidine HCl. Comprehensive analytical testing is required to verify identity, assay, and impurity levels. High-Performance Liquid Chromatography (HPLC) is the standard method for assessing chromatographic purity. Acceptable pharmaceutical specifications often dictate that individual impurities remain below 0.1%, with total impurities not exceeding 2%. Additionally, specific tests for residual solvents, heavy metals, and loss on drying are conducted to ensure compliance with pharmacopoeial standards.
Stability testing is also performed to confirm that the product maintains its specifications over time. Improper drying or packaging can lead to stability issues, such as the growth of impurities upon storage. Therefore, packaging materials must provide adequate protection against moisture ingress. A reliable global manufacturer will provide a Certificate of Analysis (COA) with every batch, detailing the results of these rigorous tests. This documentation is essential for downstream users who require technical support and validation for their own regulatory filings.
NINGBO INNO PHARMCHEM CO.,LTD. stands as a premier partner in this sector, offering consistent stable supply chains and competitive bulk price structures without compromising on quality. By leveraging advanced process controls and stringent quality assurance measures, the company ensures that every batch of DL-Histidine Monohydrochloride Monohydrate meets the highest industry standards.
Process Parameters and Specifications
| Parameter | Specification/Range | Control Method |
|---|---|---|
| Reaction Temperature | 145°C - 165°C | Thermocouple Monitoring |
| Water Content Ratio | 0.9 - 1.5 : 100 (Solvent) | Karl Fischer Titration |
| Crystallization Temp | 0°C - 5°C | Cooled Jacketed Reactor |
| Drying Temperature | 55°C - 65°C | Vacuum Oven |
| HPLC Purity | > 99.0% | Gradient UV Detection |
| Individual Impurities | < 0.1% | Chromatographic Analysis |
In conclusion, the manufacturing of DL-Histidine HCl requires a deep understanding of organic synthesis and process engineering. From the initial salt formation to the final drying and packaging, every step must be optimized to ensure product integrity. By adhering to these rigorous protocols, manufacturers can deliver a product that supports the demanding needs of the pharmaceutical and nutraceutical industries.